Muscle Weakness Duration After Single Botulinum Toxin Injection in Masseter
Status:
Active, not recruiting
Trial end date:
2022-04-10
Target enrollment:
Participant gender:
Summary
This study aimed to evaluate the duration of a reduced maximal voluntary bite force after a
botulinum toxin intervention. Methods: In an intervention group, 25 units of Xeomin® (Merz
Pharma GmbH & Co KGaA, Frankfurt am Main, Germany) botulinum neurotoxin type A were injected
into the masseter muscles bilaterally (to a total of 50 units).
Phase:
N/A
Details
Lead Sponsor:
Region Västerbotten
Collaborators:
Mahidol University Umeå University
Treatments:
abobotulinumtoxinA Botulinum Toxins Botulinum Toxins, Type A